PMC:7228307 / 4211-4482 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"48","span":{"begin":260,"end":264},"obj":"Gene"},{"id":"49","span":{"begin":48,"end":52},"obj":"Gene"}],"attributes":[{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"Gene:2213"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"Gene:2213"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ctive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host. Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR intera"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T13","span":{"begin":71,"end":77},"obj":"Disease"}],"attributes":[{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"}],"text":"ctive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host. Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR intera"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T46","span":{"begin":48,"end":50},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T47","span":{"begin":148,"end":158},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T48","span":{"begin":257,"end":259},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T49","span":{"begin":260,"end":262},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"ctive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host. Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR intera"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T12","span":{"begin":6,"end":14},"obj":"Chemical"},{"id":"T13","span":{"begin":182,"end":187},"obj":"Chemical"}],"attributes":[{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"ctive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host. Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR intera"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T21","span":{"begin":85,"end":89},"obj":"http://purl.obolibrary.org/obo/IDO_0000531"}],"text":"ctive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host. Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR intera"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"48","span":{"begin":260,"end":264},"obj":"Gene"},{"id":"49","span":{"begin":48,"end":52},"obj":"Gene"}],"attributes":[{"id":"A48","pred":"pubann:denotes","subj":"48","obj":"Gene:2213"},{"id":"A49","pred":"pubann:denotes","subj":"49","obj":"Gene:2213"}],"text":"ctive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host. Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR intera"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T10","span":{"begin":71,"end":77},"obj":"Disease"}],"attributes":[{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"}],"text":"ctive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host. Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR intera"}